Inventor · disambiguated record
Carl Arne Krister Borrebaeck
Also filed as: BORREBAECK CARL · BORREBAECK CARL A K · BORREBAECK CARL ARNE KRISTER
21 granted patents·39 pending applications·1,465 citations·filing 1994–2022
95Inventor score
Files withIMMUNOVIA AB26BORREBAECK CARL ARNE KRISTER9BIOINVENT INT AB8ALLIGATOR BIOSCIENCE AB6SENZAGEN AB4
Top patents by PatentIndex Score
60 records- 0194US6989250B2Method for in vitro molecular evolution of protein functionBIOINVENT INT AB·Filed 2002·Granted Jan 24, 2006·65 cites·49 claims
- 0293US5567610AMethod of producing human monoclonal antibodies and kit thereforBIOINVENT INT AB·Filed 1994·Granted Oct 22, 1996·1.2k cites·11 claims
- 0386US7282334B2Method for in vitro molecular evolution of protein functionALLIGATOR BIOSCIENCE AB·Filed 2005·Granted Oct 16, 2007·6 cites·7 claims
- 0485US9486520B2Compositions comprising polyglutamic acid nanoparticles and CD40 agonistsBORREBAECK CARL ARNE KRISTER·Filed 2011·Granted Nov 8, 2016·11 cites·10 claims
- 0585US6958213B2Method for in vitro molecular evolution of protein functionALLIGATOR BIOSCIENCE AB·Filed 2000·Granted Oct 25, 2005·11 cites·7 claims
- 0684US6159690AMethod for in vitro molecular evolution of protein function using exonuclease and amplificationBIOINVENT INT AB·Filed 1998·Granted Dec 12, 2000·65 cites·18 claims
- 0782US7563578B2Method for in vitro molecular evolution of protein functionALLIGATOR BIOSCIENCE AB·Filed 2007·Granted Jul 21, 2009·3 cites·6 claims
- 0882US5712089AMethod of selecting specific bacteriophagesBIOINVENT INT AB·Filed 1994·Granted Jan 27, 1998·71 cites·8 claims
- 0978US7153655B2Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequenceALLIGATOR BIOSCIENCE AB·Filed 2002·Granted Dec 26, 2006·10 cites·35 claims
- 1076US7816085B2Method for in vitro molecular evolution of protein functionALLIGATOR BIOSCIENCE AB·Filed 2009·Granted Oct 19, 2010·1 cites·6 claims
- 1174US9863960B2Method, array and use for determining the presence of pancreatic cancerBORREBAECK CARL ARNE KRISTER·Filed 2012·Granted Jan 9, 2018·2 cites·2 claims
- 1272US7432083B2Method for in vitro molecular evolution of protein functionBIOINVENT INT AB·Filed 2005·Granted Oct 7, 2008·5 cites·34 claims
- 1369US2021356478A1Method, array and use for determining the presence of pancreatic cancerIMMUNOVIA AB·Filed 2021·Application pending·0 cites
- 1469US2022390452A1Method of diagnosing or prognosing epithelial ovarian cancerIMMUNOVIA AB·Filed 2022·Application pending·0 cites
- 1568US11525832B2Protein signature/markers for the detection of adenocarcinomaIMMUNOVIA AB·Filed 2019·Granted Dec 13, 2022·0 cites·9 claims
- 1668US6027930AMethod of selecting specific bacteriophagesBIOINVENT INT AB·Filed 1996·Granted Feb 22, 2000·40 cites·16 claims
- 1768US2020088742A1Method, array and use for determining the presence of pancreatic cancerIMMUNOVIA AB·Filed 2019·Application pending·0 cites
- 1867US7262012B2Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populationsALLIGATOR BIOSCIENCE AB·Filed 2003·Granted Aug 28, 2007·3 cites·29 claims
- 1966US2022214344A1Method, array and use thereofIMMUNOVIA AB·Filed 2022·Application pending·0 cites
- 2062US2022206004A1Method, array and use thereofIMMUNOVIA AB·Filed 2021·Application pending·0 cites
- 2161US2008108507A1Method for in vitro molecular evolution of protein functionSODERLIND ULF HANS ESKIL·Filed 2007·Application pending·0 cites
- 2260US2023074480A1Biomarker signatures of systemic lupus erythematosus and uses thereofIMMUNOVIA AB·Filed 2022·Application pending·0 cites
- 2360US2018136231A1Method, Array and Use for Determining the Presence of Pancreatic CancerIMMUNOVIA AB·Filed 2017·Application pending·0 cites
- 2460US2023063017A1Biomarker signatures of systemic lupus erythematosus and uses thereofIMMUNOVIA AB·Filed 2022·Application pending·0 cites
- 2557US2019018016A1Method of diagnosing or prognosing epithelial ovarian cancerIMMUNOVIA AB·Filed 2018·Application pending·0 cites
- 2657US2019128891A1Method, array and use thereofIMMUNOVIA AB·Filed 2018·Application pending·0 cites
- 2756US10859572B2Biomarker signatures and uses thereofIMMUNOVIA AB·Filed 2018·Granted Dec 8, 2020·0 cites·9 claims
- 2856US2021189497A1Analytical methods and arrays for use in the sameSENZAGEN AB·Filed 2021·Application pending·0 cites
- 2956US2011287486A1Method for In Vitro Molecular Evolution of Protein FunctionSODERLIND ULF HANS ESKIL·Filed 2011·Application pending·0 cites
- 3056US2010105571A1Protein Signature/Markers for the Detection of AdenocarcinomaBORREBAECK CARL ARNE KRISTER·Filed 2008·Application pending·0 cites
- 3156US2017307620A1Protein signature/markers for the detection of adenocarcinomaIMMUNOVIA AB·Filed 2017·Application pending·0 cites
- 3253US10564163B2Method, array and use thereofIMMUNOVIA AB·Filed 2018·Granted Feb 18, 2020·0 cites·18 claims
- 3353US2016252513A1Method, array and use thereofIMMUNOVIA AB·Filed 2014·Application pending·0 cites
- 3451US2011217238A1Method of Diagnosing or Prognosing Epithelial Ovarian CancerBORREBAECK CARL ARNE KRISTER·Filed 2009·Application pending·0 cites
- 3550US2016047815A1Method of diagnosing or prognosing epithelial ovarian cancerIMMUNOVIA AB·Filed 2015·Application pending·0 cites
- 3650US2018284120A1Methods for determining a breast cancer-associated disease state and arrays for use in the methodsIMMUNOVIA AB·Filed 2017·Application pending·0 cites
- 3750US2013274134A1Analytical Methods and Arrays for Use in the SameLINDSTEDT MALIN·Filed 2011·Application pending·0 cites
- 3848US2017218449A1Analytical methods and arrays for use in the sameSENZAGEN AB·Filed 2017·Application pending·0 cites
- 3947US6495321B1Method for in vitro molecular evolution of protein functionBIOINVENT INT AB·Filed 1998·Granted Dec 17, 2002·9 cites·18 claims
- 4047US2009285750A1Agent, composition and methodBORREBAECK CARL·Filed 2007·Application pending·0 cites
- 4147US2015057177A1Methods for determining a breast cancer-associated disease state and arrays for use in the methodsIMMUNOVIA AB·Filed 2013·Application pending·0 cites
- 4247US2013288912A1Biomarker signatures and uses thereofBORREBAECK CARL ARNE KRISTER·Filed 2011·Application pending·0 cites
- 4346US10048265B2Methods and arrays for use in the sameIMMUNOVIA AB·Filed 2014·Granted Aug 14, 2018·0 cites·25 claims
- 4445US2020041504A1Biomarker signatures of systemic lupus erythematosus and uses thereofIMMUNOVIA AB·Filed 2017·Application pending·0 cites
- 4545US2017283874A1Analytical Methods and Arrays for Use in the SameSENZAGEN AB·Filed 2017·Application pending·0 cites
- 4645US2020057061A1Biomarker signatures of systemic lupus erythematosus and uses thereofIMMUNOVIA AB·Filed 2017·Application pending·0 cites
- 4744US2003224410A1Combined ligand and receptor displayFiled 2003·Application pending·0 cites
- 4844US2010304979A1Diagnostic Methods and Arrays for Use in the SameBORREBAECK CARL ARNE KRISTER·Filed 2008·Application pending·0 cites
- 4943US2015111771A1Method for Identifying Agents Capable of Inducing Respiratory Sensitization and Array and Analytical Kits for Use in the MethodSENZAGEN AB·Filed 2013·Application pending·0 cites
- 5043US2013143760A1Method, Array and Use ThereofBORREBAECK CARL ARNE KRISTER·Filed 2011·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Carl Arne Krister Borrebaeck files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →